Development of in vitro pharmacokinetic screens using Caco-2, human hepatocyte, and Caco-2/human hepatocyte hybrid systems for the prediction of oral bioavailability in humans

Journal of Biomolecular Screening

Volumn 12, Issue 8, 2007, Pages 1084-1091

  Li, Cheng ^a   Liu, Tongtong ^a   Cui, Xiaoming ^a   Uss, Annette S ^a   Cheng, K C ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bioavailability; Caco 2; Drug discovery; Human hepatocyte; In vitro

Indexed keywords

ACICLOVIR; ALPRENOLOL; ATENOLOL; CAFFEINE; CARBAMAZEPINE; CIMETIDINE; CORTICOSTERONE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYDROCORTISONE; KETOPROFEN; MACROGOL 400; MANNITOL; METHYLPREDNISOLONE; METOLAZONE; METOPROLOL; NADOLOL; NAPROXEN; PHENAZONE; PROPRANOLOL; RANITIDINE; SALAZOSULFAPYRIDINE; TERBUTALINE; THEOPHYLLINE; VERAPAMIL;

ARTICLE; CELL FRACTIONATION; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG PENETRATION; HUMAN; HUMAN CELL; HYBRID CELL; IN VITRO STUDY; INCUBATION TIME; LINEAR REGRESSION ANALYSIS; LIVER CELL; LIVER CLEARANCE; PREDICTION; PRIORITY JOURNAL; SCREENING TEST;

ADMINISTRATION, ORAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HEPATOCYTES; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; REFERENCE STANDARDS; TIME FACTORS;

EID: 36549002236     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057107308892     Document Type: Article

References (42)

1. Chaturvedi PR, Decker CJ, Odinecs A.: Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. Curr Opin Chem Biol 2001 ; 5: 452-463.
2. Korfmacher WA: Principles and applications of LC-MS in new drug discovery. Curr Opin Drug Discov Devel 2003 ; 6: 481-485.
3. Balimane PV, Chong S., Morrison RA: Current methodologies used for evaluation of intestinal permeability and absorption. J Phamacol Toxicol Methods 2000 ; 44: 301-312.
4. Bergstrom CAS: In silico predictions of drug solubility and permeability: two rate-limiting barriers to oral drug absorption. Basic Clin Pharmacol Toxicol 2005 ; 96: 156-161.
5. Walter E., Kissel T.: Transport of peptidomimetic renin inhibitors across monolayers of a human intestinal cell line (Caco-2): evidence for self-enhancement of paracellular transport route. J Pharm Sci 1995 ; 3: 215-230.
6. Lau YY, Sapidou E., Cui X., White RE, Cheng K-C.: Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved and sandwich-culture hepatocytes. Drug Metab Dispos 2001 ; 3: 1446-1454.
7. Brown HS, Griffin M., Houston JB: Evaluation of cryopreserved human hepatocytes as alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 2007 ; 35: 293-301.
8. Lau YY, Chen Y-H., Liu T., Li C., Cui X., White RE,, et al. Evaluation of a novel in vitro Caco-2 hepatocyte system for predicting in vivo bioavailability. Drug Metab Dispos 2004 ; 32: 937-942.
9. Cheng K-C., Li C., Hsieh Y-S., Montgomery D., Liu T., White RE: Development of a high-throughput in vitro assay using a novel Caco-2/rat hepatocyte system for the prediction of oral plasma area under the concentration versus time curve (AUC) in rats. J Pharmacol Toxicol Methods 2006 ; 53: 215-218.
10. Chong S., Dando S., Soucek K., Morrison RA: In vitro permeability through Caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. Pharm Res 1996 ; 13: 120-123.
11. Bourdet DL, Pollack GM, Thakker DR: Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells. Pharm Res 2006 ; 23: 1178-1187.
12. Saha P., Kou J.: Effect of bovine serum albumin on drug permeability estimation across Caco-2 monolayers. Eur J Pharm Biopharm 2002 ; 54: 319-324.
13. Yee S.: In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man: fact or myth. Pharm Res 1997 ; 14: 763-766.
14. Oulianova N., Cheng D., Huebert N., Chen Y.: Human oral drugs absorption is correlated to their in vitro uptake by brush border membrane vescicles. Int J Pharm 2006 ; 336: 115-121.
15. Chiou WL, Barve A.: Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 1998 ; 15: 1792-1795.
16. Chiou WL, Buchler PW: Comparison of oral absorption and bioavailability between monkey and human. Pharm Res 2002 ; 19: 868-874.
17. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG: The Pharmacological Basis of Therapeutics. 9 th ed. New York: McGraw-Hill, 1996: 1712-1792.
18. Tilstone WJ, Dargie H., Dargie EN, Morgan HG, Kennedy AC: Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure. Clin Pharmacol Ther 1974 ; 16: 322-329.
19. Pieniaszek HJ, Resertarits DE, Wilferth WW, Blumenthal HP, Bates TR: Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets. J Clin Pharmacol 1979 ; 19: 39-45.
20. Bodin NO, Borg KO, Johansson R., Obianwu H., Svensson R.: Absorption, distribution and excretion of alprenolol in man, dog and rat. Acta Pharmacol Toxicol (Copenh) 1974 ; 35: 261-269.
21. Handal KA, Schauben JL, Salamone FR: Naloxone. Ann Emerg Med 1983 ; 12: 438-445.
22. Thummel KE, Shen DD: Design and optimization of dosage regimens: pharmacokinetic data. In Hardman JG, Limbard LE, Gilman AG (eds): Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10 th ed. New York: McGraw-Hill, 2001: 1917-2023.
23. McKinney JM: Lovastatin: a new cholesterol-lowering agent. Clin Pharm 1988 ; 7: 21-36.
24. Sallee FR, Pollock BG: Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet 1990 ; 18: 346-364.
25. Das KM, Dubin R.: Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet 1976 ; 1: 406-425.
26. Transwell P., Hofgartner R., Bozler G., Giesler H., Allmendinger G., Schmid E.: Absolute bioavailability of pirenzepine in intensive care patients. Eur J Clin Pharmacol 1990 ; 38: 265-268.
27. Dunselman PHJM, Edgar B: Felodipine clinical pharmacokinetics. Clin Pharmacokinet 1991 ; 21: 418-430.
28. Singh BN, Josephson MA: Clinical pharmacology, pharmacokinetics and hemodynamic effects of nicardipine. Am Heart J 1990 ; 119: 427-434.
29. Fitton A., Benfield P.: Isradipine: a review of its pharmacodynamics and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1990 ; 40: 31-74.
30. Eichizen H., Eichelbaum M.: Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet 1986 ; 11: 425-449.
31. Colangelo PM, Blouin RA, Steinmetz JE, McNamara PJ, Demaria AN, Wedlund PJ: Age and propranolol stereoselective disposition in humans. Clin Pharmacol Ther 1992 ; 51: 489-494.
32. Sallee FR, Pollock BG: Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet 1990 ; 18: 346-364.
33. Ferron GM, Paul JC, Fruncillo RJ, Martin PT, Yacoub L., Mayer PR: Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults. J Clin Pharmacol 1999 ; 39: 945-950.
34. Benet LZ, Oie S., Schwartz JB: Design and optimization of dosage regimens: pharmacokinetic data. In Hardman JG, Limbard LE, Gilman AG (eds): Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10 th ed. New York: McGraw-Hill, 1996: 1707-1792.
35. Chang M., Tybring G., Dahl M-L., Gotharson E., Sagar M., Seensalu R.,, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995 ; 39: 511-518.
36. Jann MW, Grimsley SR, Gray EC, Chang W-H.: Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993 ; 24: 161-176.
37. Bertilsson L., Towson T.: Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide: an update. Clin Pharmacokinet 1986 ; 11: 177-198.
38. Guerret M., Cheymol G., Aubry JP, Cheymol A., Lavene D., Kiechel JR: Estimation of the absolute oral bioavailability of pindolol by two analytical methods. Eur J Clin Pharmacol 1983 ; 25: 357-359.
39. Greenblatt DJ, Wright CE: Clinical pharmacokinetics of alprazolam. Clin Pharmacokinet 1993 ; 24: 452-471.
40. Levine M., Chang T.: Therapeutic drug monitoring of phenytoin: rationale and current status. Clin Pharmacokinet 1990 ; 19: 341-358.
41. Debruyne D., Ryckelnck JP: Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993 ; 24: 10-27.
42. Greenblatt DJ, Divoll MK, Harmatz JS, Shader RI: Antipyrine absorption and disposition in the elderly. Pharmacology 1988 ; 36: 125-133.